This document outlines details of PBS-subsidised azacitidine, daunorubicin+cytarabine, decitabine+cedazuridine and midostaurin for patients with acute myeloid leukaemia (AML).
For details on how to process a PBS Authority, see:
Processing Complex Authority Required Listings
Processing new Authority requests in the Pharmaceutical Benefits Scheme (PBS), and
Processing an existing Authority request in the Pharmaceutical Benefits Scheme (PBS)
Acute myeloid leukaemia (AML) quick reference
Restrictions | Authority level and section | PA assessment | Processing system | Prescriber type | Prescriber self-serve |
Initial | Telephone Electronic S100: azacitidine injection S85: decitabine+cedazuridine (general listing) | No | OPA | Not specified | Yes |
Continuing | Streamlined S100: azacitidine injection S85: decitabine+cedazuridine (general listing) | No | N/A | Not specified | N/A |
Induction consolidation | Telephone Electronic S100: midostaurin | No | OPA | Not specified | Yes |
Initial maintenance PB253 form | Written Electronic S100: midostaurin | No | OPA | Not specified | Yes |
Continuing maintenance | Telephone Electronic S100: midostaurin | No | OPA | Not specified | Yes |
Initial treatment following intensive induction chemotherapy | Telephone Electronic S85: azacitidine tablet | No | OPA | Not specified | Yes |
Continuing treatment following intensive induction chemotherapy | Telephone Electronic S85: azacitidine tablet | No | OPA | Not specified | Yes |
Continuing treatment Dose escalation therapy PB355 form | Written Electronic S85: azacitidine tablet | No | OPA | Not specified | Yes |
Induction | Telephone Electronic S100 EFC: daunorubicin+cytarabine | No | OPA | Not specified | Yes |
Consolidation | Telephone Electronic S100 EFC: daunorubicin+cytarabine | No | OPA | Not specified | Yes |
Expand all